Cardio Diagnostics Holdings, INC 10-Q quarterly reports

Cardio Diagnostics Holdings, Inc. reported a significant revenue decrease and continued net losses for Q3 2025, alongside an identified material weakness in internal controls.

Cardio Diagnostics Holdings, Inc. reported a significant revenue decrease for the six months ended June 30, 2025, alongside a reduced net loss primarily due to lower stock compensation expenses.

Cardio Diagnostics Holdings, Inc. reported a net loss of $1.635 million on revenue of $940 for the quarter ended March 31, 2025, as the company continues to navigate a strategic shift in its commercialization efforts.

Cardio Diagnostics Holdings reported a net loss of $1.4 million for the third quarter of 2024, alongside increased revenue and ongoing efforts to navigate regulatory changes and financial constraints.

Cardio Diagnostics Holdings reported a net loss of $1.29 million for the second quarter of 2024, alongside a slight increase in revenue and ongoing efforts to navigate regulatory changes.

Cardio Diagnostics Holdings, Inc. reported a net loss of $4.16 million for the first quarter of 2024, with revenue of $15,928 and increased operating expenses.